Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 8/20 | 0.47 |
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14544918 | 1.00 | EP300 (0.47) | EP300KDM1AHTR2CHTR2BCREBBP | |
| SCHEMBL14545328 | 0.93 | CHRNB2 (0.48) | EP300KDM1A | |
| SCHEMBL14544919 | 0.92 | EP300 (0.52) | EP300KDM1ACREBBP | |
| SCHEMBL4694710 | 0.89 | EP300 (0.42) | EP300KDM1A | |
| SCHEMBL14544907 | 0.77 | CNR1 (0.45) | EP300KDM1ACREBBP | |
| SCHEMBL14545603 | 0.77 | MET (0.43) | EP300KDM1A | |
| SCHEMBL4823398 | 0.76 | HTR2C (0.48) | HTR2CHTR2B | |
| SCHEMBL13560051 | 0.76 | HTR2C (0.48) | HTR2CHTR2B | |
| SCHEMBL14544935 | 0.76 | EP300 (0.58) | EP300KDM1ACREBBP | |
| SCHEMBL14545338 | 0.75 | EP300 (0.60) | EP300KDM1ACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | EP300 609/4885KDM1A 1397/4885HTR2C 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.